FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 360:1676-1678 April 16, 2009 Number 16 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Glowacki, J. Related Article by Weinstein, R. S. PubMed Citation

To the Editor: Weinstein et al. (Jan. 1 issue)¹ report on giant osteoclast formation in women receiving long-term oral bisphosphonate therapy. In accordance with the results of their study, our findings from a study of paired biopsy specimens, reported in 2006,² showed giant osteoclast formation after 38 months in 9 of 23 men who received bisphosphonate therapy (39%). In addition to their presence in men who received alendronate, giant osteoclasts were observed when other nitrogen-containing bisphosphonates, such as risedronate and pamidronate, were administered. All these agents appeared to be associated with cytoskeletal disruption. A prolonged effect of bisphosphonates on the . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2010 Massachusetts Medical Society. All rights reserved.